Market revenue in 2023 | USD 613.2 million |
Market revenue in 2030 | USD 1,445.0 million |
Growth rate | 13% (CAGR from 2023 to 2030) |
Largest segment | Botulinum toxin type a |
Fastest growing segment | HA |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Collagen, Botulinum Toxin Type A, HA, CaHA, Polymer Fillers |
Key market players worldwide | Ipsen SA, AbbVie Inc, Medytox, Revance Therapeutics Inc, Galderma Group AG Registered Shares, Sinclair Pharma plc, Merz Pharma |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to facial injectable market will help companies and investors design strategic landscapes.
Botulinum toxin type a was the largest segment with a revenue share of 55.19% in 2023. Horizon Databook has segmented the Japan facial injectable market based on collagen, botulinum toxin type a, ha, caha, polymer fillers covering the revenue growth of each sub-segment from 2018 to 2030.
Japan is one of the most rapidly aging nations in the world. As of 2020, 25% of the country’s population was aged above 65, and this percentage is anticipated to reach nearly 40% by 2060. The rapidly aging population in the country is also anticipated to boost the market demand, as the geriatric population is more susceptible to fine lines, wrinkles, saggy skin, and other signs of aging.
Moreover, the country’s population significantly emphasizes facial features, as ~92% of cosmetic procedures performed in 2020– 2021 were related to the face. According to the ISAPS 2022 report, nearly 998,000 injectable procedures were performed in Japan, out of which 841,620 were botulinum toxin procedures and 154,806 were HA fillers.
Botulinum filler procedures accounted for 40% of the total nonsurgical procedures in the country. Moreover, the country accounted for 7.2% of the global nonsurgical procedures performed in 2022, only ranking after the U.S., which recorded 32.8% of the global nonsurgical procedures in the same year.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan facial injectable market , including forecasts for subscribers. This country databook contains high-level insights into Japan facial injectable market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account